• Fenipentol: An Identity-First Assay Strategy

  2026-09-28

  Fenipentol and 1-Phenyl-1-pentanol are examined through an identity-first framework that separates compound-specific evidence from findings on the positional isomer 1-phenyl-2-pentanol. This guide translates historical secretory observations, ESR1 docking data, and modern cell-based methods into practical assay decisions.

• ATRX Loss and RTK Inhibitor Sensitivity in Glioma

  2026-09-28

  Pladevall-Morera and colleagues report that ATRX-deficient high-grade glioma cells are more sensitive to several receptor tyrosine kinase and PDGFR inhibitors than ATRX-proficient cells, and that combining RTK inhibition with temozolomide produces pronounced toxicity in the deficient cells. The findings make ATRX status a relevant variable for preclinical drug testing and for interpreting RTK-inhibitor trials, while leaving clinical benefit and the underlying sensitivity mechanism to be established.

• Cy7 NHS Ester: Practical Labeling and QC Guide

  2026-09-27

  Sulfo-Cy7 NHS Ester provides a water-soluble near-infrared label for attaching a fluorescent reporter to accessible amino groups on proteins and peptides, including samples for in vitro or in vivo imaging workflows. It is not a substitute for a cell-permeant stain, and it should not be used when the biomolecule cannot tolerate amine modification or when a stored aqueous dye solution is required.

• Streptavidin-HyperFluor 647: Uses and Limits

  2026-09-26

  Streptavidin-HyperFluor 647 is a Streptavidin fluorescent conjugate for detecting biotinylated targets by fluorescence. This guide explains its binding and spectral properties, practical workflow considerations, and why it is not interchangeable with biotin-free click-labeling methods.

• From Variant Breadth to Assay Clarity

  2026-09-25

  Preclinical vaccine findings can inform translational assay strategy—but only when the biological question, species, and detection chemistry are kept distinct. Explore how a human IgG-specific fluorescent secondary can support downstream research while preserving those boundaries.

• Fumagillin A4407: Practical Assay Design

  2026-09-25

  A scenario-driven guide to using Fumagillin (SKU A4407) in cell-proliferation, viability, angiogenesis, and antiparasitic research. It connects the compound’s documented solubility and storage properties with evidence limits and practical assay-design decisions.

• HyperFluor 488 Goat Anti-Rabbit IgG: Use Guide

  2026-09-24

  HyperFluor™ 488 Goat Anti-Rabbit IgG (H+L) Antibody is a fluorescent secondary reagent for detecting rabbit primary antibodies in fluorescence-based assays. Use it in validated immunofluorescence, microscopy, or flow cytometry workflows; do not assume it is suitable for non-rabbit primaries or unmodified live-cell staining.

• EdU Imaging Kits (HF594) in PDAC Models

  2026-09-24

  Use EdU pulse labeling to distinguish changes in S-phase DNA synthesis from the Schwann-cell remodeling and tumor-cell migration that characterize pancreatic cancer–nerve interactions. This practical guide shows how to add a sensitive fluorescence readout to microscopy or flow cytometry workflows without treating proliferation as a proxy for invasion.

• Rational Design of IR-1061 NIR-II Liposomes

  2026-09-23

  This study shows that liposome charge and IR-1061 loading shape dye encapsulation and fluorescence, and identifies an optimized formulation for mouse vascular imaging. The work offers a formulation-level design framework for improving NIR-II signal while highlighting aggregation as a constraint on performance.

• HyperFluor 488 Goat Anti-Rabbit IgG for SCI Imaging

  2026-09-23

  Build sensitive fluorescence workflows for spinal cord injury research with a rabbit-primary-compatible secondary that supports tissue imaging, cultured-cell assays, and flow cytometry. The workflow connects pathway-focused biology with practical controls, titration, and troubleshooting for more interpretable fluorescence data.

• GTP Solution to Localized mRNA Therapy

  2026-09-22

  A translational perspective on how GTP quality influences in vitro transcription workflows and how p21 mRNA–loaded lipid nanoparticles are reshaping localized bladder cancer research.

• Ginsenosides Protect Lung and Kidney From Hypoxia

  2026-09-22

  This 2024 study identifies coordinated regulation of the PHD2/HIF-1α/EPO axis as a potential explanation for ginsenoside-mediated protection against simulated high-altitude hypoxia. By integrating physiological, hematological, histological, inflammatory, oxidative-stress, and fluorescence endpoints, the work connects improved tissue oxygenation with reduced lung and kidney injury.

• RNF166–Angiomotin Signaling in Colorectal Cancer

  2026-09-21

  The reference study identifies RNF166 as an E3 ubiquitin ligase that recognizes poly-ADP-ribosylated angiomotins and promotes their destabilization, thereby activating YAP and accelerating colorectal cancer progression. Its identification of the RNF166 Di19-ZF region as a previously underappreciated poly-ADP-ribose-binding module provides a mechanistic link between tankyrase modification, Hippo pathway control, and tumor biology.

• 2-Thio-dCTP Workflows for Precision DNA Studies

  2026-09-21

  2-Thio-dCTP enables controlled experiments in polymerase selectivity, site-specific DNA modification, and DNA-protein interaction studies. This practical guide connects its sulfur-substituted chemistry with assay design inspired by the SCP4–H3T3 chromosome-stability pathway, while separating validated nucleotide workflows from exploratory chromatin applications.

• FK866 (APO866) Workflows for NAMPT Research

  2026-09-20

  Build reproducible NAD-depletion experiments with FK866 (APO866), from AML viability profiling to mitochondrial mechanism studies. The workflow also shows how NAMPT inhibition can interrogate vascular-aging biology without confusing pathway validation with therapeutic proof.

742 records 6/50 page Previous Next First page 上5页 678910 下5页 Last page